UNASSIGNED: e16001 Background: Majority of @entity1 with @entity135 present with locally advanced disease. Most of the @entity1 are treated with concurrent chemoradiotherapy. However, the @entity137 are substantial and can be associated with severe local and systemic @entity137 . Alternate schedules of @entity900 have been tried to overcome these @entity137 . No formal comparison, however, has been reported between alternate schedules and reference regimen in literature. The primary aim is to report a retrospective study comparing alternate schedule of @entity900 with standard three weekly bolus @entity900 in terms of effectiveness and related @entity137 . METHODS: @entity1 with @entity135 who were treated with concurrent chemoradiotherapy in our center between periods of 2007-2009 were retrospectively analyzed. Basic demographics and clinical characteristics' of the @entity1 were collected. Parameters such as overall survival rate, locoregional or systemic relapse rates, and time to local/systemic relapse, which show treatment effectiveness and also main @entity137 , parameters were recorded. RESULTS: Fifty five eligible @entity1 were analyzed retrospectively. No significant difference was observed between the two groups of the study as compared to the median overall survival time. One, two, and three-year probability of survival for @entity1 in groups A and B were 75% to 65% in one year, 63% to 56% in two year, and 63% to 52% in three year, respectively. Locoregional relapse and systemic relapse were similar in both groups. Although time to local and systemic relapse was higher in group B as compared to group A, a statistical analysis was failed to show any significant difference. Furthermore, there was no significant difference between groups with respect to major @entity137 . Only development of grade III-IV @entity33 during treatment showed significant effect on OS in univariate analysis. CONCLUSIONS: In @entity1 with @entity135 , concurrent chemoradiotherapy with weekly @entity900 can be accepted as effective as concurrent chemoradiotherapy with three weekly high dose bolus @entity900 .

Weekly XXXX versus standard three-weekly @entity900 in concurrent chemoradiotherapy of @entity135 : Baskent University experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'head and neck cancers'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
